{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-151393","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.840989+00:00","generated_at":"2026-05-18T16:23:41.849981+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kymera prices $250.8M public offering of common stock and pre-funded warrants","bullets":["Offering includes 5,044,500 shares at $44.00 and pre-funded warrants for 655,500 shares at $43.9999.","Net proceeds estimated at $237.3M (or $272.7M if underwriters option for 855K shares exercised).","Proceeds to advance preclinical/clinical degrader programs and for working capital.","Existing cash plus offering proceeds expected to fund operations into mid 2028.","Company also entered registration rights agreement with Baker, Atlas, and BVF affiliates for up to 27.96M resale shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-151393","json":"https://secwatch.observer/filing/0001193125-25-151393.json","markdown":"https://secwatch.observer/filing/0001193125-25-151393.md","text":"https://secwatch.observer/filing/0001193125-25-151393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525151393/0001193125-25-151393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525151393/d85382d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T16:23:41.849981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}